Bai Feng, Pu Jun, Che Wenliang, Chen Jiyan, Chen Mao, Chen Wei, Chen Xiaoping, Chen Yundai, Cheng Xianwu, Cheng Xiang, Cong Hongliang, Dai Cuilian, Fan Dali, Fu Guosheng, Gao Lei, Gao Chuanyu, Gao Wei, Ge Junbo, He Ben, Hu Tao, Huang Congxin, Huang Jing, Huo Yong, Jia Shaobin, Jiang Jun, Jing Zhicheng, Kong Xiangqing, Li Lang, Li Yan, Li Yigang, Li Zhijuan, Liang Chun, Lin Xianhe, Liu Xianxia, Liu Xuebo, Lu Chengzhi, Ma Genshan, Ma Yitong, Mao Wei, Mei Xia, Ning Zhongping, Ou Jiafu, Slaj Shaderdin, Shen Chengxing, Shi Haiming, Shi Hong, Shi Bei, Su Xi, Sun Ningling, Tang Qizhu, Wang Fang, Wang Changqian, Wang Jin, Wu Yanqing, Wu Yongjian, Xia Yunlong, Xiang Dingcheng, Xiao Pingxi, Xie Ping, Xiong Dingding, Xu Yawei, Yang Jiefu, Yang Lixia, Yu Zaixin, Yuan Zuyi, Yuan Haitao, Zhang Guogang, Zhang Heng, Zhang Jian, Zhang Li, Zhang Ruiyan, Zhang Shuning, Zhang Shuyang, Zhang Zheng, Zhao Guoan, Zhao Xianxian, Zheng Jingang, Zheng Haoyi, Zhou Daxin, Zhou Shenghua, Zhou Yujie
The Second Hospital of Lanzhou University.
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.
Cardiol Plus. 2023 Apr-Jun;8(2):82-102. doi: 10.1097/CP9.0000000000000043. Epub 2023 Jul 20.
The primary site of infection in COVID-19 exhibit is the respiratory system, but multiple organ systems could be affected. The virus could directly invade cardiomyocytes. Alternatively, cytokine storm could lead to myocardial injury. More importantly, the management of existing cardiovascular diseases must be re-examined in COVID-19 due to, for example, interaction between antiviral agents and with a wide variety of pharmacological agents. The Branch of Cardiovascular Physicians of Chinese Medical Doctor Association organized a panel of experts in cardiovascular and related fields to discuss this important issue, and formulated the "2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases." The Consensus was drafted on the basis of systematic review of existing evidence and diagnosis and treatment experience, and covers three major aspects: myocardial injury caused by COVID-10 and COVID-19 vaccine, the impact of COVID-19 on patients with cardiovascular disease, and the impact of COVID-19 on the cardiovascular system of healthy people, and rehabilitation guidance recommendations. The Consensus involves 11 core clinical issues, including incidence, pathogenesis, clinical manifestations, treatment strategies, prognosis, and rehabilitation. It is our hope that this Consensus will provide a practical guidance to cardiologists in the management of cardiovascular diseases in the new era of COVID-19 pandemic.
新型冠状病毒肺炎(COVID-19)的主要感染部位是呼吸系统,但多个器官系统可能会受到影响。病毒可直接侵袭心肌细胞。此外,细胞因子风暴可导致心肌损伤。更重要的是,由于抗病毒药物与多种药物之间的相互作用等原因,在COVID-19中必须重新审视现有心血管疾病的管理。中华医学会心血管病学分会组织了心血管及相关领域的专家小组讨论这一重要问题,并制定了《2023年新型冠状病毒肺炎对心血管疾病管理影响的中国专家共识》。该共识在系统回顾现有证据和诊疗经验的基础上起草,涵盖三个主要方面:COVID-19和COVID-19疫苗所致心肌损伤、COVID-19对心血管疾病患者的影响、COVID-19对健康人心血管系统的影响以及康复指导建议。该共识涉及11个核心临床问题,包括发病率、发病机制、临床表现、治疗策略、预后和康复。我们希望本共识能为心血管病医生在COVID-19大流行新时代管理心血管疾病提供切实指导。